Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin - Scorecard - MDSpire

Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin

  • By

  • Christopher A. Galifi

  • Elvan Dogan

  • Luis Fernandez Almansa

  • Krystopher Maingrette

  • Simran S. Shah

  • Joseph J. Bulatowicz

  • Karen Ebenezer

  • Utz Herbig

  • Amir K. Miri

  • Teresa L. Wood

  • May 20, 2026

  • 0 min

Share

Clinical Scorecard: The Role of Insulin-like Growth Factor 1 Receptor in Modulating Breast Cancer Cell Adhesion via Beta-1 Integrin

At a Glance

CategoryDetail
Condition
Key MechanismsIGF1R modulates cancer cell adhesion through interactions with β1 integrin, influencing both adhesion and internalization processes.
Target Population
Care Setting

Key Highlights

  • Clarify that IGF1R knockdown leads to increased adhesion through β1 integrin dependency.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider specific therapeutic strategies that target IGF1R modulation in TNBC.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Discuss the implications of IGF1R inhibitors' poor efficacy on treatment planning for patients.

        Clinical Best Practices

        • Incorporate specific therapeutic approaches based on IGF1R signaling findings.

        Related Resources & Content

        Original Source(s)

        Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin

        • by Christopher A. Galifi, Elvan Dogan, Luis Fernandez Almansa, Krystopher Maingrette, Simran S. Shah, Joseph J. Bulatowicz, Karen Ebenezer, Utz Herbig, Amir K. Miri, Teresa L. Wood

        • May 20, 2026

        Related Content

        Overcoming immunotherapy resistance in triple-negative breast cancer: a critical review of mast cell plasticity, metabolic reprogramming, and organoid models

        Recent advances in dissolving microneedles for breast cancer immunotherapy: local delivery and tumor microenvironment remodeling

        Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC